Clinical trial
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688
Study timeline
Study start (actual)2022-12-01Date precision: day
Registry last updated2026-05-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Alzheimer Diseaseverified · MONDO: Alzheimer disease
Interventions
[18F]PI-2620DRUG
Sponsors & collaborators
Lantheus Biosciences Ltd.lead sponsor
Mapped research locations
Los AngelesCalifornia, United States1DallasTexas, United States1MiamiFlorida, United States1San FranciscoCalifornia, United States1PhoenixArizona, United States1JacksonvilleFlorida, United States1CharlotteNorth Carolina, United States1SyracuseNew York, United States1LincolnNebraska, United States1SarasotaFlorida, United States1LebanonNew Hampshire, United States1HialeahFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05641688 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.